Iovance Biotherapeutics, Inc. (IOVA)
| Market Cap | 2.94B +285.0% |
| Revenue (ttm) | 324.97M +34.5% |
| Net Income | -289.52M |
| EPS | -0.71 |
| Shares Out | 452.97M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,381,001 |
| Open | 6.48 |
| Previous Close | 6.40 |
| Day's Range | 6.18 - 6.53 |
| 52-Week Range | 1.76 - 6.92 |
| Beta | 0.70 |
| Analysts | Buy |
| Price Target | 9.22 (+42.07%) |
| Earnings Date | Aug 6, 2026 |
About IOVA
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients w... [Read more]
Financial Performance
In 2025, Iovance Biotherapeutics's revenue was $263.50 million, an increase of 60.60% compared to the previous year's $164.07 million. Losses were -$390.98 million, 5.05% more than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for IOVA stock is "Buy." The 12-month stock price target is $9.22, which is an increase of 42.07% from the latest price.
News
Iovance Biotherapeutics price target raised to $6 from $4 at Baird
Baird analyst Collen Kusy raised the firm’s price target on Iovance Biotherapeutics (IOVA) to $6 from $4 and keeps a Neutral rating on the shares. The firm updated its model…
Iovance Biotherapeutics price target raised to $8 from $5 at Citizens
Citizens analyst Reni Benjamin raised the firm’s price target on Iovance Biotherapeutics (IOVA) to $8 from $5 and keeps an Outperform rating on the shares. Iovance delivered strong Q2 revenue…
Iovance Biotherapeutics price target raised to $13 from $11 at Barclays
Barclays raised the firm’s price target on Iovance Biotherapeutics (IOVA) to $13 from $11 and keeps an Overweight rating on the shares post the Q2 report. Amtagvi beats expectations and…
Iovance Biotherapeutics Earnings Call Transcript: Q2 2026
Record Q2 revenue and margin were driven by robust Amtagvi demand, expanding ATC network, and operational efficiencies. Pipeline advanced with key regulatory milestones and international approvals, while strong cash reserves support ongoing growth and R&D.
Iovance Biotherapeutics Earnings release: Q2 2026
Iovance Biotherapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Iovance Biotherapeutics Quarterly report: Q2 2026
Iovance Biotherapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Iovance Biotherapeutics backs FY26 revenue view $350M-370M, consensus $352M
The company said, “Based on strong second-quarter sales and current demand trends, Iovance is reviewing its FY26 total revenue guidance of $350 million to $370 million. An update will be…
Iovance Biotherapeutics reports Q2 EPS (11c), consensus (13c)
Reports Q2 revenue $99.31M, consensus $86.5M. “Second-quarter revenue reached a record $99.3 million with gross margin of 56%, driven by continued U.S. Amtagvi demand,” said Frederick Vogt, Interim Pr...
Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates
U.S. Amtagvi Revenue Reaches ~$91M and Total Revenue Increased 66% Year-over-Year Gross Margin Increased to 56% Fast Track Designation (FTD) Granted by the FDA for Lifileucel in Soft Tissue Sarcomas S...
Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026
SAN CARLOS, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deliveri...
Iovance Biotherapeutics Slides: Corporate presentation
Iovance Biotherapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 30, 2026.
Iovance Biotherapeutics files automatic mixed securities shelf
16:34 EDT Iovance Biotherapeutics (IOVA) files automatic mixed securities shelf
Iovance Biotherapeutics Transcript: AGM 2026
Shareholders approved all proposals, including director elections, compensation, and share increases. Financials showed strong growth, robust cash position, and ambitious pipeline expansion plans. Focus remains on revenue growth, margin improvement, and advancing clinical programs.
Iovance Biotherapeutics Transcript: Jefferies Global Healthcare Conference 2026
AMTAGVI’s commercial launch is accelerating with strong U.S. and international uptake, backed by robust clinical data. The pipeline includes pivotal studies in melanoma, lung, endometrial, and sarcoma, with next-gen therapies advancing. 2024 revenue is guided at $350–$370M, and cash reserves should fund operations into 2028.
Iovance receives Australian approval of Amtagvi for advanced melanoma
Iovance Biotherapeutics (IOVA) announced that the Therapeutic Goods Administration of Australia has granted conditional approval of Amtagvi for previously treated advanced melanoma. Amtagvi is a tumor...
Iovance's Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy
Iovance gets allowance to proceed from FDA for IOV-5001 IND application
Iovance Biotherapeutics (IOVA) announced allowance to proceed from the FDA for the investigational new drug, or IND, application for a Phase 1/2 basket trial of IOV-5001, a next-generation interleukin...
Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001
Next-Generation Platform Expands into Solid Tumors Representing 100,000+ U.S. Deaths Annually SAN CARLOS, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a com...
Iovance Biotherapeutics to Present at Upcoming Conference
SAN CARLOS, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infi...
Iovance Biotherapeutics price target lowered to $14 from $16 at Chardan
Chardan lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $14 from $16 and keeps a Buy rating on the shares. The firm is adjusting its model to reflect…
Iovance Biotherapeutics reports Q1 EPS (19c), consensus (15c)
Reports Q1 revenue $71.43M, consensus $75.66M. Frederick Vogt, interim President and Chief Executive Officer of Iovance, stated, “We are accelerating the adoption and commercial expansion for Amtagvi ...
Iovance Biotherapeutics sees Q2 revenue $86M-$88M, consensus $84.36M
Sees Q2 Amtagvi revenue $79M-$81M.
Iovance Biotherapeutics sees FY26 revenue $350M-$370M, consensus $359.68M
08:11 EDT Iovance Biotherapeutics (IOVA) sees FY26 revenue $350M-$370M, consensus $359.68M
Iovance Biotherapeutics Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 45% year-over-year, driven by strong AMTAGVI demand and operational efficiencies. Guidance for Q2 and full-year 2026 remains robust, with margins expected to improve and a broadening pipeline targeting multiple solid tumor indications.